echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Clinuvel's Scenese (afamelanotide) is approved for listing by FDA

    Clinuvel's Scenese (afamelanotide) is approved for listing by FDA

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, the u.SFDA(http://announced the approval of Clinuvel(http://development of Scenesse (http:// to treat adult patients with skin damage caused by red blood cell-generating protosin rickets
    about Afamelaide
    a black skin quality-1 receptor agonistAfamelanotide is asynthetic(http://polypeptide, a similar to the alpha-melanocyte stimulation hormone (alpha-MSH)Alpha-MSH is a naturally occurring peptide hormone in the human bodyAfamelanotide is released by skin cells under the stimulation of ultraviolet lightAlpha-MSH stimulates melanin cell production and releases melanin, which has the effect of protecting the skin from light damage   Afamelanotide replaces two amino acids in alpha-MSH, improving molecular stability and potency It increases the skin's melanin levels without uv rays   Afamelanotide has been eligible for orphan drug and priority review by the FDA   The efficacy of Afamelanotide was demonstrated in two clinical trial series (http:// In one trial, a total of 93 patients with red blood cell-generating protoscoccal radon were tested and 48 patients were treated with afamelanotide   The results showed that during the 180 days of treatment, patients in the afamelanotide group had a total of 64 hours of painless exposure, significantly higher than in the placebo group (41 hours)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.